Concepedia
Statistics
Publications
4
Citations
1.3K
H-Index
Active since
2015
Affiliations
Novartis (Switzerland)(Current)
University of Southern California
Retinal Consultants of Arizona
James Warburton is an author at Novartis (Switzerland) specializing in ocular pharmacology, ophthalmology, and macular disease.
Publications per year
2015–2019
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel, Adrian Koh, Yuichiro Ogura et al. · Ophthalmology · 2019 · 911 citations · Full text
Medicine, Ophthalmology, Pharmacotherapy +16
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial
Pravin U. Dugel, Glenn J. Jaffe, Peter Sallstig et al. · Ophthalmology · 2017 · 232 citations
Medicine, Ophthalmology, Pharmacotherapy +13
Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD
Sebastian M. Waldstein, Jonathan Wright, James Warburton et al. · Ophthalmology · 2015 · 126 citations · Full text
Medicine, Ophthalmology, Vision Science +17
Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment
Ian Pearce, Sanjiv Banerjee, Ben Burton et al. · Ophthalmology · 2015 · 49 citations
Medicine, Ophthalmology, Pharmacology +8
1–4 of 4